Table 1.
Demographical and clinical characteristics of studied population.
| WF/IFNE (n = 12) | PPF/PF (n = 13) | APF/PH (n = 4) | p value | |
|---|---|---|---|---|
| Age (years)* (median ± SD) | 30.7 ± 10.2 | 35.0 ± 10.9 | 60.7 ± 4.1 | <0.05b,c |
| Female gender n (%)** | 6 (50) | 8 (61.5) | 3 (75.0) | ns |
| SEA-Specific IgE (%) | 75% | 67% | 67% | ns |
|
Size of left lobe (mm)
(mean ± SD) |
92.2 ± 12.4 | 94.0 ± 11.3 | 119.3 ± 21.1 | ns |
|
Periportal wall measurement (mm)
(mean ± SD) |
3.5 ± 0.71 | 4.5 ± 1.2 | 4.9 ± 1.3 | 0.0007a,b |
| Treatment report less than 1 year (%)** | 91.7 | 100 | 75 | <0.0001a,b,c |
*Kruskal-wallis test; ** Fisher’s exact test; WF/IFNE, without fibrosis/incipient fibrosis not excluded; PPF/PF, possible periportal fibrosis/periportal fibrosis; APF/PH, advanced periportal fibrosis/advanced periportal fibrosis + portal hypertension.
aWF/IFNE vs. PPF/PF; bWF/IFNE vs. APF/PH; cPPF/PF vs. APF/PH. ns, not significant (p>0.05).